Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights...
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US World Meds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories.

List your booth number for exhibitions, ask us